Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SLBT | PRESS-RELEASE | neutral | 4/10 | 🔒SL Science reported H1 2026 revenue of $1.39M (+23% YoY) and a net loss of $2.16M, widening from $1.60M. The company hig | Oct 26, 2026 |
| LYCA | PRESS-RELEASE | neutral | 5/10 | 🔒Lycia Therapeutics closed its upsized initial public offering of 20,286,000 shares at $18.00 per share, raising approxim | Oct 26, 2026 |
| CTOR | PRESS-RELEASE | neutral | 4/10 | 🔒Citius Oncology reported preliminary Q4 FY2026 unit sales of 792 LYMPHIR units to U.S. wholesalers, a 120% increase from | Oct 26, 2026 |
| LLY | PRESS-RELEASE | neutral | 2/10 | 🔒Eli Lilly declared a Q4 2026 dividend of $1.73 per share, payable December 10, 2026, to shareholders of record on Novemb | Oct 26, 2026 |
| AKBA | PRESS-RELEASE | bullish | 6/10 | 🔒Akebia Therapeutics announced positive VOICE trial data for Vafseo (vadadustat) presented at ASN Kidney Week, showing st | Oct 26, 2026 |
| LGVN | PRESS-RELEASE | mixed | 6/10 | 🔒Longeveron announced updated results from its Phase 2b ELPIS II trial of laromestrocel in HLHS. The trial missed the pri | Oct 26, 2026 |
| EQ | PRESS-RELEASE | neutral | 4/10 | 🔒Equillium dosed the first subject in a Phase 1 trial of EQ504, an oral AhR modulator for inflammatory diseases, triggeri | Oct 26, 2026 |
| QUCY | PRESS-RELEASE | neutral | 2/10 | 🔒Quantum Cyber presented its antenna technology at QuantumCT's Phase 3 Pilot Collaboration RFP Convening on Quantum Sensi | Oct 26, 2026 |
| XLO | PRESS-RELEASE | neutral | 4/10 | 🔒Xilio Therapeutics announced dosing of the first patient in a Phase 1/2 trial of XTX501, a PD-1/masked IL-2 bispecific, | Oct 26, 2026 |
| IMRX | PRESS-RELEASE | neutral | 3/10 | 🔒Immuneering presented a trial-in-progress poster at ESMO 2026 for its pivotal Phase 3 trial (MAPKeeper 301) evaluating a | Oct 26, 2026 |
| MGNX | PRESS-RELEASE | bullish | 6/10 | 🔒MacroGenics announced positive interim Phase 2 LINNET data for lorigerlimab in clear cell gynecologic cancer (CCGC), sho | Oct 26, 2026 |
| ABOS | PRESS-RELEASE | neutral | 5/10 | 🔒Acumen Pharmaceuticals reported a Q3 2026 net loss of $25.4M ($0.35 per share), slightly narrower than the year-ago $26. | Oct 26, 2026 |
| REGN | PRESS-RELEASE | neutral | 3/10 | 🔒Regeneron expanded its existing BARDA procurement agreement for Inmazeb, its FDA-approved Ebola treatment, adding approx | Oct 26, 2026 |
| EIKN | PRESS-RELEASE | bullish | 6/10 | 🔒Eikon Therapeutics presented updated Phase 2 data for its TLR7/8 agonist EIK1001 in first-line stage 4 NSCLC at ESMO 202 | Oct 26, 2026 |
| BNTX | PRESS-RELEASE | bearish | 6/10 | 🔒BioNTech and DualityBiologics announced that the Phase 3 DYNASTY-Breast02 trial of trastuzumab pamirtecan (BNT323/DB-130 | Oct 26, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | 🔒HUTCHMED announced positive Phase III SANOVO trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in fir | Oct 26, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | 🔒HUTCHMED announced positive Phase III SAFFRON trial results for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in ME | Oct 25, 2026 |
| ORKA | PRESS-RELEASE | neutral | 6/10 | Oruka Therapeutics will report Week 16 data for its lead candidate ORKA-001 from the EVERLAST-B Phase 2b trial in plaque | Oct 25, 2026 |
| AVBP | PRESS-RELEASE | bullish | 5/10 | ArriVent BioPharma announced encouraging initial Phase 1 results for ARR-217, a CDH17-targeting ADC, in heavily pretreat | Oct 25, 2026 |
| AMRN | PRESS-RELEASE | mixed | 6/10 | Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (icosapent ethyl) in colorectal cancer liver metastases | Oct 25, 2026 |
| NBP | PRESS-RELEASE | bullish | 7/10 | NovaBridge presented updated Phase 1b data for givastomig at ESMO 2026, showing an 79% objective response rate and 16.9- | Oct 25, 2026 |
| REGN | PRESS-RELEASE | bullish | 5/10 | Regeneron announced longer-term Phase 3 C-POST data at ESMO 2026 showing adjuvant Libtayo (cemiplimab) in high-risk cuta | Oct 25, 2026 |
| BNTX | PRESS-RELEASE | bullish | 6/10 | BioNTech and BMS reported first Phase 2 data from the ROSETTA Lung-107 trial showing pumitamig plus docetaxel achieved a | Oct 25, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics announced publication of positive Phase 2/3 COMPANION-002 results for tovecimig in advanced biliary | Oct 24, 2026 |
| IMTX | PRESS-RELEASE | bullish | 6/10 | Immatics presented updated Phase 1b data for IMA402 PRAME bispecific and Phase 1 data for IMA203CD8 PRAME cell therapy a | Oct 24, 2026 |
| CLYM | PRESS-RELEASE | bullish | 7/10 | Climb Bio reported additional Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, at ASN Kidney | Oct 23, 2026 |
| AVBP | PRESS-RELEASE | bullish | 7/10 | ArriVent announced that initial safety and efficacy data from the Phase 1 study of its CDH17-targeted ADC ARR-217 (MRG00 | Oct 23, 2026 |
| PRFX | PRESS-RELEASE | neutral | 5/10 | PRF Technologies issued a shareholder letter highlighting a strengthened balance sheet with $11M cash and $2.5M liabilit | Oct 23, 2026 |
| ENLV | PRESS-RELEASE | neutral | 3/10 | Enlivex announced a 1-for-16 reverse stock split effective October 27, 2026, to regain compliance with Nasdaq listing re | Oct 22, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma announced a 1-for-10 reverse stock split effective October 26, 2026, to regain compliance with Nasdaq' | Oct 22, 2026 |
Page 1 of 82 Next »